Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Kreuznach – page 57

739 clinical trials in Bad Kreuznach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Kreuznach at a glance
739
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

739 trials in Bad Kreuznach

Open in trial search

Portal hypertension

Not recruiting

Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Regorafenib and Pembrolizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Translational Research In Oncology

Study on Nalbuphine ER for Treating Cough in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nalbuphine Hydrochloride
  • Sponsor:Trevi Therapeutics Inc.

Oral lichen planus+1

Not recruiting

Study on the Effectiveness of Deucravacitinib for Patients with Lichen Planus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Y-mAbs Therapeutics A/S

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Venglustat and Imiglucerase for Adult Patients with Gaucher Disease TYPE 3

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Imiglucerase
  • Sponsor:Genzyme Corp.

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Cholangiocarcinoma+1

Not recruiting

Study on the Effectiveness and Safety of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab for Untreated HER2-Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Migraine+2

Not recruiting

Study on Long-Term Safety of Atogepant for Preventing Migraine in Patients with Chronic or Episodic Migraine

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Kite Pharma Inc.

Study on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Kreuznach

What the registry says about research in the country

01 Neonatal Care Research

Clinical trials focusing on improving oxygen administration in extremely preterm infants, investigating automated versus manual control systems to enhance respiratory support outcomes.

  • Respiratory Support Management
  • Oxygen Therapy Control
  • Premature Birth Complications

This innovative research aims to evaluate the effectiveness of closed-loop automatic control systems in preventing complications such as ROP, NEC, and BPD while monitoring long-term neurocognitive development in premature babies.

02 Pediatric Intensive Care

Studies examining advanced respiratory support technologies for infants born between 23 and 27 weeks of gestational age, with a focus on optimizing ventilation strategies.

  • Mechanical Ventilation
  • CPAP Management
  • Oxygen Therapy Safety

The research, supported by the German Federal Ministry for Education and Research, explores improvements in neonatal intensive care practices to enhance survival rates and reduce complications.

03 Long-term Developmental Outcomes

Investigation into the long-term effects of oxygen therapy management on neurocognitive development in premature infants, tracked over a 24-month period.

  • Developmental Assessment
  • Mortality Prevention
  • Quality of Life Improvement

This comprehensive study evaluates both immediate medical outcomes and extended developmental progress in extremely preterm infants receiving different oxygen administration methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.